share_log

广济药业(000952.SZ):恩替卡韦原料药上市申请获批

Guangji Pharmaceutical (000952.SZ): Entecavir API marketing application approved

Zhitong Finance ·  Nov 6, 2023 06:29

According to the Zhitong Finance App, Guangji Pharmaceutical (000952.SZ) announced that recently, the company received entecavir's “Notice of Approval of Marketing Application for Chemical Raw Materials” issued by the State Drug Administration. According to reports, entecavir is a guanine nucleoside analogue and has an inhibitory effect on hepatitis B virus polymerase. It is suitable for the treatment of chronic adult hepatitis B where virus replication is active, serum alanine aminotransferase (ALT) continues to rise, or liver histology shows active lesions.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment